AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32205528 — intervention group
Group type: EXPERIMENTAL
Intervention: Same experimenter-participant race
Number of subjects: 372
Study 32205528 — intervention group
Group type: EXPERIMENTAL
Intervention: Different sex of experimenter and participant
Number of subjects: 372
Study 35959712 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-particle (LP) size graft (1000–2000 μm)
Number of subjects: 22
Study 35959712 — intervention group
Group type: COMPARATOR
Intervention: Small-particle (SP) size graft (250–1000 μm)
Number of subjects: 22
Study 35959712 — intervention group
Group type: COMPARATOR
Intervention: Control group (LP)
Number of subjects: 22
Study 32148181 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurse-led asthma intervention
Number of subjects: 0
Study 33541772 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection (PAI)
Number of subjects: 0
Study 33541772 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain control (non-PAI)
Number of subjects: 0
Study 32812320 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab 800 mg every 2 weeks in combination with gemcitabine and nab-paclitaxel
Number of subjects: 36
Study 33213288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 147
Study 33213288 — intervention group
Group type: COMPARATOR
Intervention: No intravenous alteplase
Number of subjects: 147
Study 33213288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recanalization
Number of subjects: 147
Study 33213288 — intervention group
Group type: COMPARATOR
Intervention: No early recanalization
Number of subjects: 147
Study 32538889 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback flutter device
Number of subjects: 168
Study 32538889 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback flutter device
Number of subjects: 168
Study 32538889 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory biofeedback flutter device
Number of subjects: 168
Study 32538889 — intervention group
Group type: COMPARATOR
Intervention: Conventional flutter device
Number of subjects: 168
Study 32795167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 239
Study 32795167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 33825512 — intervention group
Group type: EXPERIMENTAL
Intervention: PVE with N-Butyl-Cyanoacrylate (NBCA) plus iodized oil
Number of subjects: 60
Study 33825512 — intervention group
Group type: COMPARATOR
Intervention: PVE with Polyvinyl Alcohol (PVA) particles plus coils
Number of subjects: 60
Study 34579049 — intervention group
Group type: EXPERIMENTAL
Intervention: Test fermented milk containing yogurt and Lacticaseibacillus strains (L. paracasei CNCM I‐1518 and I‐3689, L. rhamnosus CNCM I‐3690) for 28 days
Number of subjects: 136
Study 34579049 — intervention group
Group type: COMPARATOR
Intervention: Control product for 28 days
Number of subjects: 136
Study 35429325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent mask CPAP (ICPAP)
Number of subjects: 96
Study 35429325 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous helmet CPAP (HCPAP)
Number of subjects: 96
Study 33914256 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02 (bevacizumab biosimilar)
Number of subjects: 627
Study 33914256 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab (15 mg/kg)
Number of subjects: 627
Study 33914256 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02
Number of subjects: 627
Study 33914256 — intervention group
Group type: COMPARATOR
Intervention: EU-bevacizumab
Number of subjects: 627
Study 33914256 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02 and EU-bevacizumab
Number of subjects: 627
Study 35428320 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg/week
Number of subjects: 100
Study 35428320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide Risk Management (SRM) protocol
Number of subjects: 51
Study 32956255 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 51
Study 32772617 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (Soliris®)
Number of subjects: 0
Study 32772617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34348263 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional L-carnitine (1,500 mg/day) and rifaximin (1,200 mg/day)
Number of subjects: 83
Study 34348263 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin (1,200 mg/day)
Number of subjects: 83
Study 32207689 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (Deprexis) with email support
Number of subjects: 223
Study 37002653 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, CBP 200 mg three times daily)
Number of subjects: 339
Study 37002653 — intervention group
Group type: COMPARATOR
Intervention: BPC quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, BPC 240 mg twice daily)
Number of subjects: 339
Study 33116029 — intervention group
Group type: EXPERIMENTAL
Intervention: cream-type denture adhesive
Number of subjects: 200
Study 33116029 — intervention group
Group type: EXPERIMENTAL
Intervention: powder-type denture adhesive
Number of subjects: 200
Study 33116029 — intervention group
Group type: COMPARATOR
Intervention: control (saline solution)
Number of subjects: 200
Study 32744919 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm PBMT (BFR strengthening with 660 nm PBMT‐35 mW; 0.05 cm2; 2.10 J, total energy 18.9 J)
Number of subjects: 58
Study 32744919 — intervention group
Group type: COMPARATOR
Intervention: 830 nm PBMT (BFR strengthening with 830 nm PBMT‐32 mW; 0.101 cm2; 1.92 J, total energy 17.2 J)
Number of subjects: 58
Study 32744919 — intervention group
Group type: COMPARATOR
Intervention: BFR (strengthening with blood flow restriction)
Number of subjects: 58
Study 32744919 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm PBMT (BFR strengthening with 660 nm PBMT)
Number of subjects: 58
Study 32744919 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional strengthening)
Number of subjects: 58
Study 32744919 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm PBMT
Number of subjects: 58
Study 35099030 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction initially preferred, followed by open reduction with percutaneous pinning when necessary.
Number of subjects: 112
Study 32979921 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 412
Study 36037823 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 7372
Study 36037823 — intervention group
Group type: COMPARATOR
Intervention: Control (hepatitis E vaccine)
Number of subjects: 7372
Study 34383535 — intervention group
Group type: EXPERIMENTAL
Intervention: Group mindfulness-based cognitive therapy (MBCT)
Number of subjects: 148
Study 34383535 — intervention group
Group type: COMPARATOR
Intervention: Group supportive sex education and therapy (STEP)
Number of subjects: 148
Study 34383535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 148
Study 35965904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional tranexamic acid (TXA) 4 mg/mL
Number of subjects: 68
Study 35965904 — intervention group
Group type: COMPARATOR
Intervention: Topical Kligman's therapy
Number of subjects: 68
Study 36401254 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 90
Study 36401254 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 90
Study 36109141 — intervention group
Group type: EXPERIMENTAL
Intervention: Third COVID-19 vaccination with an mRNA vaccine
Number of subjects: 60
Study 34469855 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal condition (no ADS failure)
Number of subjects: 261
Study 34469855 — intervention group
Group type: COMPARATOR
Intervention: Fault condition (ADS failure)
Number of subjects: 261
Study 34469855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (normal and fault)
Number of subjects: 261
Study 34469855 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 261
Study 32767712 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate colour photograph (CP)
Number of subjects: 30
Study 32767712 — intervention group
Group type: COMPARATOR
Intervention: Black-and-white line drawing (LD)
Number of subjects: 30
Study 35309844 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder combined with photodynamic therapy (PDT)
Number of subjects: 110
Study 35309844 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 110
Study 35309844 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder combined with PDT
Number of subjects: 110
Study 33629961 — intervention group
Group type: EXPERIMENTAL
Intervention: POP4Teens (P4T)
Number of subjects: 406
Study 33629961 — intervention group
Group type: COMPARATOR
Intervention: JustThinkTwice (JTT)
Number of subjects: 406
Study 32623011 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the right temporo-parietal junction (TPJ)
Number of subjects: 0
Study 32623011 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS applied to the left temporo-parietal junction (TPJ)
Number of subjects: 0
Study 35030270 — intervention group
Group type: EXPERIMENTAL
Intervention: Revitalization with the blood clot (BC) technique
Number of subjects: 20
Study 35030270 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)-based technique
Number of subjects: 20
Study 35030270 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 20
Study 34230452 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI decrease to less than 0.02% at the first tumor evaluation
Number of subjects: 125
Study 34230452 — intervention group
Group type: EXPERIMENTAL
Intervention: high-level pretreatment mTBI
Number of subjects: 125
Study 34230452 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI as a biomarker
Number of subjects: 125
Study 34230452 — intervention group
Group type: EXPERIMENTAL
Intervention: molecular responders
Number of subjects: 125
Study 34230452 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI in ctDNA
Number of subjects: 125
Study 32632703 — intervention group
Group type: EXPERIMENTAL
Intervention: Displacement without reduction (DWoR) group (n = 25)
Number of subjects: 47
Study 32632703 — intervention group
Group type: EXPERIMENTAL
Intervention: Displacement with reduction (DWR) group (n = 32)
Number of subjects: 47
Study 32632703 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal disc position (ND) group (n = 37)
Number of subjects: 47
Study 32632703 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-temporomandibular joint disc displacement (non-TMJD) patients
Number of subjects: 47
Study 33894496 — intervention group
Group type: EXPERIMENTAL
Intervention: 61.2 Gy concomitant boost (CB)
Number of subjects: 140
Study 33894496 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy daily (QD)
Number of subjects: 140
Study 33894496 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide chemotherapy with TRT regimens
Number of subjects: 140
Study 32605881 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention delivered by lay health coaches
Number of subjects: 221
Study 33357808 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging Treatment Model
Number of subjects: 230
Study 35445986 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO2R
Number of subjects: 18
Study 35445986 — intervention group
Group type: COMPARATOR
Intervention: NIV
Number of subjects: 18
Study 33620233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein hypocaloric diet (diet HP)
Number of subjects: 269
Study 33620233 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 269
Study 32366124 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (38 participants)
Number of subjects: 222
Study 32366124 — intervention group
Group type: COMPARATOR
Intervention: Advice (33 participants)
Number of subjects: 222
Study 32366124 — intervention group
Group type: COMPARATOR
Intervention: Device (39 participants)
Number of subjects: 222
Study 35028950 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 16
Study 35028950 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 16
Study 35028950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 16
Study 35028950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 34278743 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance plus moderate endurance training
Number of subjects: 31
Study 34278743 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate endurance training only
Number of subjects: 31
Study 34278743 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants (hCON)
Number of subjects: 31
Study 32054355 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO + ALA
Number of subjects: 23
Study 32054355 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 36164047 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DA-EPOCH-21
Number of subjects: 140
Study 36164047 — intervention group
Group type: EXPERIMENTAL
Intervention: R-mNHL-BFM-90
Number of subjects: 140
Study 36164047 — intervention group
Group type: COMPARATOR
Intervention: R-DA-EPOCH-21 ± auto-HSCT
Number of subjects: 140
Study 36164047 — intervention group
Group type: COMPARATOR
Intervention: R-mNHL-BFM-90 ± auto-HSCT
Number of subjects: 140
Study 34292298 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mode (collision warning device providing alerts via vibrotactile wristbands)
Number of subjects: 31
Study 34292298 — intervention group
Group type: COMPARATOR
Intervention: Silent mode (collision warning device detecting collisions without providing warnings)
Number of subjects: 31
Study 34292298 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mode
Number of subjects: 31
Study 32740327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Map-Based Life Review Program (MBLRP) plus routine care
Number of subjects: 84
Study 32740327 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 84
Study 33983396 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to non-menthol cigarettes
Number of subjects: 122
Study 33983396 — intervention group
Group type: COMPARATOR
Intervention: Continue smoking menthol cigarettes
Number of subjects: 122
Study 32896022 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Panax quinquefolius
Number of subjects: 0
Study 32896022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34282720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glutamate diet
Number of subjects: 0
Study 34282720 — intervention group
Group type: COMPARATOR
Intervention: Monosodium glutamate (MSG) challenge
Number of subjects: 0
Study 34534488 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention including screening for cardiovascular risk factors, structured lifestyle interventions, linkage to primary health-care, and active follow-up.
Number of subjects: 1671
Study 34534488 — intervention group
Group type: COMPARATOR
Intervention: Usual care group receiving one-time counselling and annual screening for risk factors.
Number of subjects: 1671
Study 35368763 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleeb Bua Daeng (KBD) formula, 1,000 mg twice a day for three months
Number of subjects: 40
Study 35368763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35368763 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleeb Bua Daeng (KBD) formula
Number of subjects: 40
Study 33862582 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 293
Study 33862582 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine + erlotinib
Number of subjects: 293
Study 35312788 — intervention group
Group type: EXPERIMENTAL
Intervention: Be ACTIVE
Number of subjects: 50
Study 35312788 — intervention group
Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 50
Study 33253210 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antifungal treatment with adjunctive dexamethasone
Number of subjects: 211
Study 33253210 — intervention group
Group type: COMPARATOR
Intervention: Standard antifungal treatment without adjunctive dexamethasone
Number of subjects: 211
Study 34450354 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenofemoral ligation and stripping (SFL/S)
Number of subjects: 122
Study 34450354 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 122
Study 33647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine KIM-1
Number of subjects: 2253
Study 33647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine MCP-1
Number of subjects: 2253
Study 33647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine A1M
Number of subjects: 2253
Study 33647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine B2M
Number of subjects: 2253
Study 33647393 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine albumin
Number of subjects: 2253
Study 32039689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 1)
Number of subjects: 22
Study 32039689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 2)
Number of subjects: 22
Study 32039689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragrance inhalation of grapefruit essential oil (last 5 minutes of inhalation)
Number of subjects: 22
Study 34106270 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of external control data into interim analyses (IAs)
Number of subjects: 0
Study 32608134 — intervention group
Group type: COMPARATOR
Intervention: ARE0 (0 g kg-1)
Number of subjects: 24
Study 32608134 — intervention group
Group type: EXPERIMENTAL
Intervention: ARE20 (20 g kg-1)
Number of subjects: 24
Study 32608134 — intervention group
Group type: EXPERIMENTAL
Intervention: ARE50 (50 g kg-1)
Number of subjects: 24
Study 32608134 — intervention group
Group type: EXPERIMENTAL
Intervention: ARE80 (80 g kg-1)
Number of subjects: 24
Study 32608134 — intervention group
Group type: EXPERIMENTAL
Intervention: ARE (5% to 8% DMI)
Number of subjects: 24
Study 34971398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 39
Study 34971398 — intervention group
Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 39
Study 33060555 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular scheduled ibuprofen (10 mg/kg per dose, maximum 600 mg every 6 hours)
Number of subjects: 99
Study 33060555 — intervention group
Group type: COMPARATOR
Intervention: Pro re nata (PRN) ibuprofen
Number of subjects: 99
Study 33060555 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular scheduled ibuprofen
Number of subjects: 99
Study 34456194 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH administration (3 times daily for 7 days)
Number of subjects: 9
Study 34456194 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 4)
Number of subjects: 9
Study 33560444 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 121
Study 33560444 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 121
Study 32632489 — intervention group
Group type: EXPERIMENTAL
Intervention: WI plus L-TAP
Number of subjects: 102
Study 32632489 — intervention group
Group type: COMPARATOR
Intervention: WI
Number of subjects: 102
Study 32651140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament flavum preservation technique
Number of subjects: 251
Study 32651140 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedures
Number of subjects: 251
Study 32991232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation group (CR) with standard medical treatments and exercise-based cardiac rehabilitation
Number of subjects: 70
Study 32991232 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard medical treatments without exercise
Number of subjects: 70
Study 32991232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation group (CR)
Number of subjects: 70
Study 32991232 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 33129628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic intervention to improve communication (4 weekly sessions)
Number of subjects: 64
Study 35742692 — intervention group
Group type: EXPERIMENTAL
Intervention: USD 0.40 incentive for every USD 1.00 spent
Number of subjects: 77
Study 35742692 — intervention group
Group type: EXPERIMENTAL
Intervention: USD 2 incentive for every USD 1.00 spent (2:1)
Number of subjects: 77
Study 35742692 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive program at the highest level (2:1)
Number of subjects: 77
Study 33035598 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 6000
Study 33035598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 37258803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) + Sitagliptin (100 mg) + Metformin (1000 mg) ER
Number of subjects: 415
Study 37258803 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg) + Metformin (1000 mg) SR
Number of subjects: 415
Study 37258803 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin (10 mg) + Metformin (1000 mg) ER
Number of subjects: 415
Study 37258803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Sitagliptin + Metformin ER
Number of subjects: 415
Study 34235909 — intervention group
Group type: EXPERIMENTAL
Intervention: InGaAsP and Er,Cr:YSGG laser adjunctive to subgingival debridement
Number of subjects: 42
Study 34235909 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement alone
Number of subjects: 42
Study 32338946 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 90
Study 32338946 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 90